Recent News for AKTX - Akari Therapeutics Plc

Date Title
Apr 13 Circling Back On Akari Therapeutics
Apr 13 25 Stocks Moving in Tuesday's Pre-Market Session
Apr 12 Akari Therapeutics' To Go With Pivotal Bullous Pemphigoid Study With Nomacopan
Apr 12 Akari shares rise on Bullous Pemphigoid nomacopan late-stage study initiation
Apr 12 Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)
Mar 4 Akari Therapeutics inks nomacopan deal with U.S. Army in trauma
Mar 4 Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma
Feb 25 Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies
Feb 25 Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis
Feb 23 The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Feb 2 Is Akari Therapeutics, Plc (NASDAQ:AKTX) Popular Amongst Insiders?
Feb 1 Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease
Jan 21 The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
Jan 6 Akari Therapeutics to Participate in Two January Virtual Investor Conferences
Dec 11 Akari Therapeutics reports Q3 results
Dec 11 Akari Therapeutics updates trial progress; returns to profitability
Dec 11 Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
Dec 11 Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Dec 3 Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease
Dec 3 Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease
Dec 1 Akari Therapeutics (NASDAQ:AKTX) Will Have To Spend Its Cash Wisely
Oct 27 Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29
Back to the Main AKTX Page...